艾曲泊帕联合免疫抑制治疗儿童重型再生障碍性贫血:2期ESCALATE试验
ESCALATE是一项2期试验,评估艾曲泊帕联合免疫抑制治疗(IST)用于1至<18岁复发/难治(R/R)或初治重型再生障碍性贫血(SAA)患儿。51例患者接受治疗(R/R 14例,初治37例);26周总缓解率(ORR)合并为54.9%,R/R队列为71.4%,初治队列为48.6%;R/R队列ORR呈有利趋势,未见新的安全性信号。
要点
- 26周ORR合并为54.9%,R/R队列71.4%,初治队列48.6%。
- 基线输血依赖者中66.7%脱离红细胞输注、76.7%脱离血小板输注。
- 最常见治疗相关不良事件为肝功能检查异常,包括胆红素升高43.1%。
核心结论
- 艾曲泊帕联合IST在儿童R/R或初治SAA中显示R/R队列ORR呈有利趋势,且未见新的安全性信号。
研究设计与样本
- 2期ESCALATE试验纳入1至<18岁R/R或初治SAA患者,共51例接受治疗(R/R 14例,初治37例),数据按总体及R/R、初治2个队列分析。
主要发现
- 26周ORR(按北美儿童再生障碍性贫血联盟标准)合并为54.9%,R/R队列为71.4%,初治队列为48.6%,多数缓解者在停用艾曲泊帕后维持缓解。
- 基线输血依赖患者中,66.7%脱离红细胞输注、76.7%脱离血小板输注;R/R队列分别为70%和80%,初治队列分别为65.6%和75.8%。
- 最常见治疗相关不良事件为肝功能检查异常,包括胆红素升高43.1%、丙氨酸氨基转移酶升高37.3%、天冬氨酸氨基转移酶升高33.3%。
关键数值与推荐
- 艾曲泊帕起始剂量:1至<6岁25 mg/d,6至<18岁50 mg/d,允许调整剂量(最大150 mg/d)以达到50×109/L至200×109/L的目标血小板计数。
- 艾曲泊帕与环孢素A联用,可联合或不联合马抗胸腺细胞球蛋白,疗程26周,如临床获益可延长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to <18 years) with relapsed/refractory (R/R) or treatment-naïve SAA. The eltrombopag starting dose was 25 mg/d for patients aged 1 to <6 years and 50 mg/d for patients aged 6 to <18 years; dose modifications (maximum dose, 150 mg/d) were allowed to achieve a target platelet count of 50 × 109/L to 200 × 109/L. Eltrombopag was administered with cyclosporine A, with or without horse antithymocyte globulin, for 26 weeks and could be extended if clinically beneficial. Fifty-one patients were treated (R/R SAA, n = 14; treatment-naïve SAA, n = 37). Data were analyzed overall and as 2 cohorts: R/R and treatment-naïve cohorts. The overall response rate (ORR; per North American Pediatric Aplastic Anemia Consortium criteria) at 26 weeks was 54.9% in both cohorts combined and 71.4% and 48.6% in the R/R and treatment-naïve cohorts, respectively; most responders had sustained responses after discontinuing eltrombopag. Among baseline transfusion-dependent patients, 66.7% and 76.7% achieved red blood cell and platelet transfusion independence, respectively, with rates of 70% and 80% for the R/R cohort and 65.6% and 75.8% for the treatment-naïve cohort, respectively. The most common treatment-related adverse events were abnormalities in liver function tests, including increased bilirubin (43.1%), alanine aminotransferase (37.3%), and aspartate aminotransferase (33.3%). Eltrombopag with IST showed a trend toward a favorable ORR in the R/R cohort, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT03025698.
引用
- Shimamura A, Maschan A, Bennett C, et al. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025. PMID: 40315366. doi:10.1182/bloodadvances.2024015102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。